May 28 |
Altamira Therapeutics Provides Business Update
|
May 23 |
Altamira stock soars 45% on Bentrio social media postings
|
May 23 |
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
|
May 1 |
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
|
Apr 24 |
Altamira reports publication of positive results from NASAR clinical trial with Bentrio
|
Apr 24 |
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
|
Apr 17 |
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024
|
Apr 10 |
Altamira Therapeutics Ltd. 2023 Q4 - Results - Earnings Call Presentation
|
Apr 10 |
Altamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call Transcript
|
Apr 10 |
Altamira Therapeutics GAAP EPS of -CHF14.80
|